Mendel Biotechnology, Inc.
Arriva Pharmaceuticals, Inc.
Venture Law Group
Fried, Frank, Harris Shriver & Jacobson LLP
Greg has over 20 years’ experience in structuring and negotiating a broad range of strategic R&D collaborations, and advising biotech companies on corporate development strategies, including joint ventures, M&A transactions, and venture and non-dilutive financings.
Prior to joining the firm, Greg was CEO of Mendel Biotechnology, Inc., where he led the successful sale of Mendel’s operating business, and subsequently led the team after the acquisition in building out its platform and team focused on developing new microbial products. During his tenure at Mendel, Greg also served as Senior Vice President, Corporate Development, where he led the financial and business case analysis of a microbial-focused platform development effort that helped drive a successful acquisition. Additionally, Greg served for many years as General Counsel, advising on corporate governance matters, negotiating collaboration agreements with BP, Bayer Crop Sciences and Monsanto Company, successfully completing an equity financing, and overseeing regulatory matters, including participation in the BIO trade association. Greg also served as General Counsel for a venture-backed biologics company developing therapies for asthma and COPD.
Before his industry experience, Greg was a partner at Venture Law Group, where he focused on licensing and strategic collaborations for both technology and life sciences companies, including (life sciences) AlgoRx Pharmaceuticals, Bayer Pharmaceuticals, CardioDx, Entelos, FivePrime Therapeutics, Threshold Pharmaceuticals, and (technology) Calix Networks, Cerent (acquired by Cisco), Intel Corporation, Intuit, Oracle and Yahoo!